ABIO ARCA Biopharma

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that , Chief Financial Officer, will present at the being held August 17-18, 2021.

ARCA is scheduled to present on Wednesday, August 18, 2021 at 1:15 PM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at: .

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit or follow the Company on .

Investor & Media Contact:

Derek Cole

720.940.2163



EN
16/08/2021

Underlying

ABIOARCA Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARCA Biopharma

 PRESS RELEASE
Free
ABIO ARCA BIOPHARMA

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics ...

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024 WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced completion of the merger with Oruka Therapeutics, Inc. (“Oruka”) following ARCA’s successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockhold...

August 29, 2024 1 EN
 PRESS RELEASE
Free
ABIO ARCA BIOPHARMA

ARCA biopharma Provides Update Regarding Special Dividend Amount in Co...

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA’s common stock, payable on August 28, 2024, to ARCA’s stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA’s Board of Directors on August 16, 2024, in connection wit...

August 26, 2024 1 EN
 PRESS RELEASE
Free
ABIO ARCA BIOPHARMA

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection wi...

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated cl...

August 23, 2024 1 EN
 PRESS RELEASE
Free
ABIO ARCA BIOPHARMA

ARCA biopharma Declares Special Dividend in Connection with the Propos...

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”) pursuant to the Agreemen...

August 16, 2024 1 EN
 PRESS RELEASE
Free
ABIO ARCA BIOPHARMA

ARCA biopharma Announces Second Quarter 2024 Financial Results and Pro...

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the “Board”) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic r...

August 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch